Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Evofem Biosciences, Inc. (EVFM) had Return on Tangible Equity of 7.44% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.90M |
|
$-5.49M |
|
$0.41M |
|
$0.49M |
|
$5.47M |
|
$-4.57M |
|
$-0.90M |
|
$-5.47M |
|
$-5.47M |
|
$-5.47M |
|
$-5.47M |
|
$-5.46M |
|
$-5.47M |
|
$-4.57M |
|
$-4.46M |
|
133.25M |
|
133.25M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$6.06M |
|
$0.42M |
|
$1.39M |
|
$7.44M |
|
$78.75M |
|
-- |
|
$1.40M |
|
$80.15M |
|
$-77.63M |
|
$-73.49M |
|
$-72.71M |
|
132.53M |
|
| Cash Flow Statement Financials | |
$2.30M |
|
$-0.00M |
|
$-0.50M |
|
$0.58M |
|
$2.38M |
|
$1.80M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-- |
|
-0.72 |
|
54.39% |
|
-508.23% |
|
-508.23% |
|
-- |
|
-608.01% |
|
-610.12% |
|
$2.30M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.22 |
|
1.61 |
|
56.06 |
|
7.04% |
|
|
Return on Tangible Equity |
7.44% |
-73.46% |
|
7.52% |
|
$-0.55 |
|
$0.02 |
|
$0.02 |
|